Trial · NCT05291598

Meloxicam for Pain Management After Total Joint Arthroplasty (TJA)

NCT05291598, Phase 3, Completed, University of Miami; results first posted 2024-08-14

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Meloxicam for Pain Management After Total Joint Arthroplasty (TJA). Trials, record NCT05291598. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05291598

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Meloxicam for Pain Management After Total Joint Arthroplasty (TJA)
NCT number: NCT05291598
Status: Completed
Phases: Phase 3
Enrollment: 223 participants, actual
Lead sponsor: University of Miami
Conditions: Total Knee Replacement, Total Hip Replacement
Interventions: IV meloxicam, Ketorolac
First posted: 2022-03-22
Last updated: 2024-08-14
Results first posted: 2024-08-14

Source ClinicalTrials.gov

Registered outcomes10

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Pain Measured by the Numeric Rating Scale	2 hours postoperatively	A numeric pain rating scale will be used - a higher pain score would indicate higher pain levels. It is scaled from 0-10.
Primary	Pain Measured by the Numeric Rating Scale	24 hours postoperatively	A numeric pain rating scale will be used - a higher pain score would indicate higher pain levels. It is scaled 0-10.
Secondary	Nausea Score as Measured by a Likert Scale	2 hours postoperatively	Patients select a score to indicate the severity of their nausea. Scores of 0, 1-2, 3-6, and 7-9 indicate no nausea, mild nausea, moderate nausea, and severe nausea, respectively. The score 10 is assigned to vomiting.
Secondary	Nausea Score as Measured by a Likert Scale	24 hours postoperatively	Patients select a score to indicate the severity of their nausea. Scores of 0, 1-2, 3-6, and 7-9 indicate no nausea, mild nausea, moderate nausea, and severe nausea, respectively. The score 10 is assigned to vomiting.
Secondary	Length of Stay as Measured by Hours in the Hospital	Until patient discharged from the hospital	Length of stay for the patient as measured in hours from surgery until the moment of discharge
Secondary	Length of Stay as Measured by Hospital Nights	From surgery until discharge	The total number of overnights spent in the hospital between surgery and discharge
Secondary	Length of Stay as Measured by Same Day Discharges	From surgery until discharge	The number of patients which were able to be discharged home the same day as their surgical procedure
Secondary	Opioid Consumption as Measured by Morphine Milligram Equivalents (MME)	Within 2 hours postoperatively	The amount of opioids a patient consumes converted into MME for standard comparisons
Secondary	Opioid Consumption as Measured by Morphine Milligram Equivalents (MME)	Within 24 hours postoperatively	The amount of opioids a patient consumes converted into MME for standard comparisons
Secondary	Renal Injury as Measured by the Change in Creatinine Levels	From preoperative baseline labs while hospitalized, up to 1 week	The change in creatinine levels per patient as by comparing their standard preoperative lab creatinine values with the standard postoperative lab creatinine values before discharge from the hospital after their procedure, up to 1 week postoperatively.

Source ClinicalTrials.gov

Outcomes10

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Pain Measured by the Numeric Rating Scale	2 hours postoperatively	15 patients in the ketorolac group and 24 in the Meloxicam group did not return survey data in the time period analyzed for this variable and were thus excluded.	units on a scale	MEAN
PRIMARY	Pain Measured by the Numeric Rating Scale	24 hours postoperatively	20 patients in the ketorolac group and 25 in the Meloxicam group did not return survey data in the time period analyzed for this variable and were thus excluded.	units on a scale	MEAN
SECONDARY	Nausea Score as Measured by a Likert Scale	2 hours postoperatively	16 patients in the ketorolac group and 24 in the Meloxicam group did not return survey data in the time period analyzed for this variable and were thus excluded.	score on a scale	MEAN
SECONDARY	Nausea Score as Measured by a Likert Scale	24 hours postoperatively	21 patients in the ketorolac group and 26 in the Meloxicam group did not return survey data in the time period analyzed for this variable and were thus excluded.	score on a scale	MEAN
SECONDARY	Length of Stay as Measured by Hours in the Hospital	Until patient discharged from the hospital		hours	MEAN
SECONDARY	Length of Stay as Measured by Hospital Nights	From surgery until discharge		nights	MEAN
SECONDARY	Length of Stay as Measured by Same Day Discharges	From surgery until discharge		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Opioid Consumption as Measured by Morphine Milligram Equivalents (MME)	Within 2 hours postoperatively		morphine milligram equivalents	MEAN
SECONDARY	Opioid Consumption as Measured by Morphine Milligram Equivalents (MME)	Within 24 hours postoperatively		morphine milligram equivalents	MEAN
SECONDARY	Renal Injury as Measured by the Change in Creatinine Levels	From preoperative baseline labs while hospitalized, up to 1 week	28 patients in the ketorolac group and 24 in the Meloxicam group did not have available data in the time period analyzed for this variable and were thus excluded. Both Arm/Groups had the same reporting identical values.	mg/dL	MEAN

Source ClinicalTrials.gov

Results by group20

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Pain Measured by the Numeric Rating Scale	Ketorolac Group	3.34	Standard Deviation 3.25	units on a scale
Pain Measured by the Numeric Rating Scale	IV Meloxicam Group	3.32	Standard Deviation 3.39	units on a scale
Pain Measured by the Numeric Rating Scale	Ketorolac Group	4.06	Standard Deviation 3.07	units on a scale
Pain Measured by the Numeric Rating Scale	IV Meloxicam Group	3.75	Standard Deviation 3.19	units on a scale
Nausea Score as Measured by a Likert Scale	Ketorolac Group	0.42	Standard Deviation 1.62	score on a scale
Nausea Score as Measured by a Likert Scale	IV Meloxicam Group	0.54	Standard Deviation 1.80	score on a scale
Nausea Score as Measured by a Likert Scale	Ketorolac Group	0.48	Standard Deviation 1.53	score on a scale
Nausea Score as Measured by a Likert Scale	IV Meloxicam Group	0.29	Standard Deviation 0.96	score on a scale
Length of Stay as Measured by Hours in the Hospital	Ketorolac Group	37.87	Standard Deviation 49.81	hours
Length of Stay as Measured by Hours in the Hospital	IV Meloxicam Group	41.56	Standard Deviation 34.30	hours

1 to 10 of 20Source ClinicalTrials.gov

See all 20 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Ketorolac Group	114
Overall Study	STARTED	IV Meloxicam Group	109
Overall Study	COMPLETED	Ketorolac Group	114
Overall Study	COMPLETED	IV Meloxicam Group	109
Overall Study	NOT COMPLETED	Ketorolac Group	0
Overall Study	NOT COMPLETED	IV Meloxicam Group	0

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

Total	Group	At risk
Total, all-cause mortality	Ketorolac Group	114
Total, all-cause mortality	IV Meloxicam Group	109
Total, other adverse events	Ketorolac Group	114
Total, other adverse events	IV Meloxicam Group	109
Total, serious adverse events	Ketorolac Group	114
Total, serious adverse events	IV Meloxicam Group	109

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
41167538	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Ketorolac Group vs IV Meloxicam Group: Length of Stay as Measured by Same Day Discharges	Trial comparisons
Ketorolac Group vs IV Meloxicam Group: deaths from any cause	Trial comparisons
Ketorolac Group vs IV Meloxicam Group: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05291598

GET https://conductscience.org/api/trials/v1/NCT05291598/registered

API reference For AI assistants